| Operating Revenue TTM | ₹27,148.4 CrAnnualized |
|---|---|
| Market Cap | ₹1,13,513.26 CrPharmaceuticals |
| Net Profit TTM | ₹5,040 Cr9.57% EPS Growth |
| Day RSI | 57.66Neutral Zone |
Key highlights
- Shield™ MCD test identifies signals for 10 cancers including breast, lung, and colorectal through a single blood draw
- Targeted at individuals aged 45 or older at typical average risk for cancer
- The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration
- Zydus holds an exclusive agreement with Nasdaq-listed Guardant Health to market the test in India
- Distribution will be facilitated through Apollo Cancer Centres' integrated healthcare platform
The Product — Shield MCD Test
The Shield Multi-Cancer Detection (MCD) test is a sophisticated methylation-based liquid biopsy designed to identify cancer-associated signals from a single blood draw. It is specifically developed to screen for ten of the most prevalent cancers, including bladder, colorectal, breast, prostate, and lung cancer, in individuals aged 45 and older. Unlike traditional screening methods that often require invasive procedures or localized imaging, this test offers a minimally invasive alternative for those at average risk.
The technology has notably received the U.S. Food and Drug Administration's Breakthrough Device Designation, highlighting its potential for more effective early-stage screening compared to current diagnostic standards.
Commercial Opportunity in India
- India recorded over 1.41 million new cancer diagnoses and 900,000 deaths in 2022
- Breast and oral cancers remain the leading causes of cancer-related mortality in the country
- Cancer screening rates in India are currently low, with significant disparity among northern and central regions
- The Shield test aims to bridge this gap by providing accessible screening through Apollo’s extensive hospital network
- Zydus’s exclusive partnership with Guardant Health provides a first-mover advantage in precision oncology diagnostics
Strategic Fit and Portfolio Expansion
This collaboration aligns with Zydus’s stated objective of transforming from a traditional pharmaceutical manufacturer into a comprehensive healthcare solutions provider. By integrating precision diagnostics into its oncology vertical, Zydus strengthens its presence in the high-growth cancer care market. The company already maintains a robust portfolio of therapeutics, biologicals, and vaccines, making the addition of early-detection diagnostics a logical vertical integration.
This move specifically targets the unmet need for proactive healthcare in India, where late-stage diagnosis remains a significant barrier to successful treatment outcomes and higher survival rates.
Management Perspective
As India’s leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield™ MCD in India, expanding access to an innovative screening technology that complements existing screening pathways.
Business Overview
Zydus Lifesciences is a global innovation-driven company employing over 30,000 people, including a dedicated team of 1,500 R&D scientists. The company has historically focused on developing and marketing a broad range of healthcare therapies across diverse segments. Its partner, Guardant Health, is a Nasdaq-listed leader in precision oncology, specializing in advanced blood and tissue tests and AI-driven analytics.
Apollo Hospitals, the third pillar of this MoU, operates one of the world’s largest integrated healthcare platforms with over 78 hospitals and 2,500 diagnostic centres, providing the necessary infrastructure to scale the Shield test across the Indian territory.
“Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India. By bringing together innovation, scientific excellence, and a shared commitment to better health outcomes, we can empower individuals to take charge of their health, enable earlier diagnosis, and significantly improve the chances of successful treatment.”
“We are pleased to bring the Shield Multi-Cancer Detection (MCD) test to India through Apollo Cancer Centres and our longstanding commercial partner Zydus Lifesciences. Earlier detection has the potential to transform cancer outcomes, and Shield MCD represents an important advancement in helping identify cancer-associated signals through a single blood draw.”
| Share price | ₹1128.1 |
|---|---|
| Market capitalisation | ₹1.14L Cr |
| Revenue (annual) | ₹27,148.40 Cr |
| Net profit (annual) | ₹5,040.00 Cr |
| Revenue (latest quarter) | ₹7,587.00 Cr+10.53% vs previous quarter |
| Net profit (latest quarter) | ₹1,272.50 Cr+22.11% vs previous quarter |
| P/E (TTM) | 22.52×Sector 42.06× |
| Promoter holding | 75.01%+0.01% QoQ |
| FII holding | 6.89%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Zydus Lifesciences Ltd. announcing a Memorandum of Understanding with Apollo Hospitals for cancer screening tests. Market figures from a third-party data provider.
